Book contents
- Multiple Sclerosis
- Multiple Sclerosis
- Copyright page
- Contents
- Preface
- Chapter 1 Autoimmune CNS Emergencies
- Chapter 2 Clinical Features of Multiple Sclerosis
- Chapter 3 Multiple Sclerosis Phenotypes
- Chapter 4 Diagnostic Evaluation
- Chapter 5 Differential Diagnosis
- Chapter 6 Neuroimaging in Multiple Sclerosis and Its Mimics
- Chapter 7 Disease-Modifying Therapies
- Chapter 8 Treatment Goals
- Chapter 9 Symptomatic Management
- Chapter 10 Reproductive Issues
- Chapter 11 Pediatric Multiple Sclerosis
- Chapter 12 Useful Websites
- Appendices
- Index
- Plate Section (PDF Only)
- References
Chapter 9 - Symptomatic Management
Published online by Cambridge University Press: 10 February 2021
Book contents
- Multiple Sclerosis
- Multiple Sclerosis
- Copyright page
- Contents
- Preface
- Chapter 1 Autoimmune CNS Emergencies
- Chapter 2 Clinical Features of Multiple Sclerosis
- Chapter 3 Multiple Sclerosis Phenotypes
- Chapter 4 Diagnostic Evaluation
- Chapter 5 Differential Diagnosis
- Chapter 6 Neuroimaging in Multiple Sclerosis and Its Mimics
- Chapter 7 Disease-Modifying Therapies
- Chapter 8 Treatment Goals
- Chapter 9 Symptomatic Management
- Chapter 10 Reproductive Issues
- Chapter 11 Pediatric Multiple Sclerosis
- Chapter 12 Useful Websites
- Appendices
- Index
- Plate Section (PDF Only)
- References
Summary
Symptoms of multiple sclerosis (MS) vary considerably from person to person and change over time. Most of these symptoms can be alleviated, but very few can be eliminated completely. Not all symptoms associated with MS are directly related to inflammation of the central nervous system. Although treatment of the disease itself is of major importance, treatment of secondary symptoms is equally important, as failure to do so can compromise quality of life for both patients and their families. In this chapter, we discuss the most common MS-related symptoms and their management. It is important to keep in mind that all treatments used have the potential for side effects. For some symptoms, nondrug approaches are the best initial approach to treatment. Potential difficulties associated with some forms of treatment are also discussed.
- Type
- Chapter
- Information
- Multiple SclerosisA Practical Manual for Hospital and Outpatient Care, pp. 157 - 176Publisher: Cambridge University PressPrint publication year: 2021
References
Yang, CC. Bladder management in multiple sclerosis. Phys Med Rehabil Clin North Am. 2013;24(4):673–86. https://doi.org/10.1016/j.pmr.2013.06.004CrossRefGoogle ScholarPubMed
Fowler, CJ, Panicker, JN, Drake, M, et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009;80(5):470–7. doi:10.1136/jnnp.2008.159178Google Scholar
Kragt, JJ, Hoogervorst, ELJ, Uitdehaag, BMJ, Polman, CH. Relation between objective and subjective measures of bladder dysfunction in multiple sclerosis. Neurology. 2004;63(9):1716–8. doi:10.1212/01.WNL.0000143062.43325.C8CrossRefGoogle ScholarPubMed
Chataway, J, Schuerer, N, Alsanousi, A, et al. Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, Phase 2 trial. Lancet. 2014;383(9936):2213–21. doi:10.1016/S0140-6736(13)62242-4Google Scholar
Frohman, TC, Castro, W, Shah, A, et al. Symptomatic therapy in multiple sclerosis. Ther Adv Neurol Disord. 2011;4(2):83–98. doi:10.1177/1756285611400658CrossRefGoogle ScholarPubMed
DasGupta, R, Fowler, CJ. Bladder, bowel and sexual dysfunction in multiple sclerosis. Drugs. 2003;63(2):153–66. doi:10.2165/00003495-200363020-00003CrossRefGoogle ScholarPubMed
Rosti‐Otajärvi, EM, Hämäläinen, PI. Neuropsychological rehabilitation for multiple sclerosis. Cochrane Database Syst Rev. 2014;(2). doi:10.1002/14651858.CD009131.pub3Google Scholar
Krupp, LB, Christodoulou, C, Melville, P, et al. Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology. 2004;63(9):1579–85. doi:10.1212/01.WNL.0000142989.09633.5AGoogle Scholar
Patti, F. Treatment of cognitive impairment in patients with multiple sclerosis. Expert Opin Investig Drugs. 2012;21(11):1679–99. doi:10.1517/13543784.2012.716036CrossRefGoogle ScholarPubMed
He, D, Zhang, Y, Dong, S, et al. Pharmacological treatment for memory disorder in multiple sclerosis. Cochrane Database Syst Rev. 2013;(12). doi:10.1002/14651858.CD008876.pub3Google Scholar
Langdon, DW, Amato, MP, Boringa, J, et al. Recommendations for a brief international cognitive assessment for multiple sclerosis (BICAMS). Mult Scler. 2012;18(6):891–8.Google Scholar
Feinstein, A. Multiple sclerosis, disease modifying treatments and depression: a critical methodological review. Mult Scler J. 2000;6(5):343–48. doi:10.1177/135245850000600509Google Scholar
Geraldes, R, Ciccarelli, O, Barkhof, F, et al. The current role of MRI in differentiating multiple sclerosis from its imaging mimics. Nat Rev Neurol. 2018;14(4):199–213. doi:10.1038/nrneurol.2018.14CrossRefGoogle ScholarPubMed
Sati, P, Oh, J, Todd Constable, R, et al. The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol. 2016;12(12):714–22. doi:10.1038/nrneurol.2016.166Google Scholar
Kearney, H, Miller, DH, Ciccarelli, O. Spinal cord MRI in multiple sclerosis: diagnostic, prognostic and clinical value. Nat Rev Neurol. 2015;11(6):327–38. doi:10.1038/nrneurol.2015.80Google Scholar
Baloh, RW. Vestibular neuritis. N Engl J Med. 2003;348(11):1027–32. doi:10.1056/NEJMcp021154Google Scholar
Kish, T. Promising multiple sclerosis agents in late-stage development. PT. 2018;43(12):750–72. www.ncbi.nlm.nih.gov/pubmed/30559588Google Scholar
Tzelepis, GE, McCool, FD. Respiratory dysfunction in multiple sclerosis. Respir Med. 2015;109(6):671–9. doi:10.1016/j.rmed.2015.01.018CrossRefGoogle ScholarPubMed
Yan, Y, Li, Y, Fu, Y, et al. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD. Sci China Life Sci. 2016;59(12):1270–81. doi:10.1007/s11427-015-4997-yGoogle Scholar
Neuteboom, R, Wilbur, C, Van Pelt, D, et al. The spectrum of inflammatory acquired demyelinating syndromes in children. Semin Pediatr Neurol. 2017;24(3):189–200. doi:10.1016/j.spen.2017.08.007Google Scholar
Sands, MJ, Levitin, A. Basics of magnetic resonance imaging. Semin Vasc Surg. 2004;17(2):66–82. doi:10.1053/j.semvascsurg.2004.03.011Google Scholar
Radue, EW, Bendfeldt, K, Mueller-Lenke, N, et al. Brain atrophy: an in-vivo measure of disease activity in multiple sclerosis. Swiss Med Wkly. 2013;143:1–11. doi:10.4414/smw.2013.13887Google Scholar
Pucci, E, Branãs, P, D’Amico, R, et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2007;2007(1):CD002818. doi:10.1002/14651858.CD002818.pub2Google Scholar
Barrett, CL, Mann, GE, Taylor, PN, Strike, P. A randomized trial to investigate the effects of functional electrical stimulation and therapeutic exercise on walking performance for people with multiple sclerosis. Mult Scler J. 2009;15(4):493–504. doi:10.1177/1352458508101320CrossRefGoogle ScholarPubMed
Goodman, AD, Brown, TR, Krupp, LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet. 2009;373(9665):732–8. doi:10.1016/S0140-6736(09)60442-6Google Scholar
Fischer, C, Mauguière, F, Ibanez, V, et al. The acute deafness of definite multiple sclerosis: BAEP patterns. Electroencephalogr Clin Neurophysiol. 1985;61(1):7–15. doi:10.1016/0013-4694(85)91066-1Google Scholar
Gelfand, JM. Multiple Sclerosis: Diagnosis, Differential Diagnosis, and Clinical Presentation. Vol 122. Goodin, DS, ed. Amsterdam: Elsevier; 2014. doi:10.1016/B978-0-444-52001-2.00011-X.Google ScholarPubMed
Eriksson, M, Andersen, O, Runmarker, B. Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler. 2003;9:260–74.CrossRefGoogle ScholarPubMed
Scalfari, A, Neuhaus, A, Daumer, M, et al. Early relapses, onset of progression, and late outcome in multiple sclerosis. JAMA Neurol. 2013;70(2):214–22. doi:10.1001/jamaneurol.2013.599Google Scholar
Olek, MJ. Differential diagnosis, clinical features, and prognosis of multiple sclerosis. Curr Clin Neurol Mult Scler. 2005:15–53.Google Scholar
Willis, MA, Fox, RJ. Progressive multiple sclerosis. Continuum (Minneap Minn). 2016;22(3):785–98. doi:10.1007/978-1-4471-2395-8Google ScholarPubMed
Wingerchuk, DM, Carter, JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014;89(2):225–40. doi:10.1016/j.mayocp.2013.11.002Google Scholar
Nyquist, PA, Cascino, GD, Rodriguez, M. Seizures in patients with multiple sclerosis seen at Mayo Clinic, Rochester, Minn, 1990–1998. Mayo Clin Proc. 2001;76(10):983-986. doi:10.4065/76.10.983Google Scholar
Sarioglu, B, Serdaroglu, G, Tutuncuoglu, S, Ozer, EA. The use of botulinum toxin type A treatment in children with spasticity. Pediatr Neurol. 2003;29(4):299–301. doi:10.1016/S0887-8994(03)00269-8Google Scholar
Feinstein, A, Freeman, J, Lo, AC. Treatment of progressive multiple sclerosis: what works, what does not, and what is needed. Lancet Neurol. 2015;14(2):194–207.Google Scholar
Coyle, PK. Symptom management and lifestyle modifications in multiple sclerosis. Continuum (Minneap Minn). 2016;22(3):815–36. doi:10.1212/CON.0000000000000325Google Scholar
Tornes, L, Conway, B, Sheremata, W. Multiple sclerosis and the cerebellum. Neurol Clin. 2014;32:957–77.Google Scholar
Ingram, G, Hirst, CL, Robertson, NP. What is the risk of permanent disability from a multiple sclerosis relapse? Neurology. 2010;75(9):837.CrossRefGoogle ScholarPubMed
Ching, B, Mohamed, A, Khoo, T, Ismail, H. Multiphasic disseminated encephalomyelitis followed by optic neuritis in a child with gluten sensitivity. Mult Scler J. 2015;21(9):1209–11. doi:10.1177/Google Scholar
Freedman, MS, Rush, CA. Severe, highly active, or aggressive multiple sclerosis. Continuum (Minneap Minn). 2016;22(3):761–84. doi:10.1212/CON.0000000000000331Google Scholar